

Supplementary Table 2. Patient characteristics for first-line chemotherapy

| Characteristic | Bortezomib-based | Lenalidomide-based | Alkylating agent-based | <i>p</i> value |
|-------------------------------------|------------------|--------------------|------------------------|----------------|
| Total | 27 (31.4) | 17 (19.8) | 42 (48.8) | |
| Age (yr) | 82 (80–87) | 84 (80–90) | 82 (80–88) | 0.108 |
| Sex, male | 15 (55.6) | 7 (41.2) | 19 (45.2) | 0.633 |
| ECOG PS | | | | 0.409 |
| 0 | 0 (0.0) | 1 (5.9) | 1 (2.4) | |
| 1 | 8 (29.6) | 4 (23.5) | 3 (7.1) | |
| 2 | 12 (44.4) | 5 (29.4) | 24 (57.1) | |
| 3 | 6 (22.2) | 5 (29.4) | 13 (31.0) | |
| 4 | 1 (3.7) | 2 (11.8) | 1 (2.4) | |
| CCI | | | | 0.048 |
| ≤ 4 | 7 (25.9) | 2 (11.8) | 18 (42.9) | |
| > 4 | 20 (74.1) | 15 (88.2) | 24 (57.1) | |
| ISS | | | | 0.740 |
| I | 2 (7.4) | 1 (5.9) | 4 (9.5) | |
| II | 6 (22.2) | 3 (17.6) | 11 (26.2) | |
| III | 19 (70.4) | 13 (76.5) | 26 (61.9) | |
| R-ISS | | | | 0.869 |
| I | 1 (3.7) | 1 (5.9) | 2 (4.8) | |
| II | 11 (40.7) | 5 (29.4) | 14 (33.3) | |
| III | 11 (40.7) | 8 (47.1) | 19 (45.2) | |
| High-risk cytogenetic abnormalities | 6 (24.0) | 8 (53.3) | 4 (11.8) | 0.017 |
| Cycle | 3 (1–9) | 3 (1–20) | 3.5 (1–54) | 0.050 |
| Early mortality | 2 (7.4) | 3 (17.6) | 8 (19.0) | 0.414 |
| Response of treatment | | | | 0.523 |
| sCR | 1 (3.7) | 0 (0.0) | 1 (2.4) | |
| CR | 2 (11.1) | 1 (5.9) | 2 (4.8) | |
| VGPR | 3 (11.1) | 2 (11.8) | 1 (2.4) | |
| PR | 8 (29.6) | 7 (41.2) | 10 (23.8) | |
| MR | 1 (3.7) | 1 (5.9) | 4 (9.5) | |
| SD | 7 (25.9) | 1 (5.9) | 10 (23.8) | |
| PD | 1 (3.7) | 0 (0.0) | 3 (7.1) | |
| Unknown | 3 (11.1) | 5 (29.4) | 11 (26.2) | |
| Median event free survival (mo) | 13.4 | 8.5 | 9.6 | 0.428 |

Values are presented as number (%) or median (range).

ECOG PS, Eastern Cooperative Oncology Group Performance Status; CCI, Charlson comorbidity index; ISS, International Staging System; R-ISS, Revised International Staging System; sCR, stringent complete response; CR, complete response; VGPR, very good partial response; PR, partial response; MR, minimal response; SD, stable disease; PD, progressive disease.